Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia

[1]  CT Collins,et al.  Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets , 2016, Oncogene.

[2]  Nicholas D. Adams,et al.  New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. , 2015, Nature chemical biology.

[3]  A. Papavassiliou,et al.  HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival. , 2015, Leukemia research.

[4]  Tudor I. Oprea,et al.  Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes , 2015, Cell.

[5]  J. Hanover,et al.  A little sugar goes a long way: The cell biology of O-GlcNAc , 2015, The Journal of cell biology.

[6]  S. Schreiber,et al.  Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia , 2015 .

[7]  T. Golub,et al.  Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. , 2015, Cell reports.

[8]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[9]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[10]  H. Kaufman,et al.  Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress , 2014, Neoplasia.

[11]  Peter Kraft,et al.  Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development , 2014, Nature Medicine.

[12]  M. Bryś,et al.  O-GlcNAcylation and Metabolic Reprograming in Cancer , 2014, Front. Endocrinol..

[13]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[14]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[15]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[16]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[17]  J. Hanover,et al.  Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation , 2012, Nature Reviews Molecular Cell Biology.

[18]  Charles Y. Lin,et al.  DHODH modulates transcriptional elongation in the neural crest and melanoma , 2011, Nature.

[19]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[20]  William H. Bisson,et al.  The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor , 2010, PloS one.

[21]  R. Gentleman,et al.  Independent filtering increases detection power for high-throughput experiments , 2010, Proceedings of the National Academy of Sciences.

[22]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[23]  P. Shannon,et al.  Exome sequencing identifies the cause of a Mendelian disorder , 2009, Nature Genetics.

[24]  Tudor I. Oprea,et al.  Detection of Intracellular Granularity Induction in Prostate Cancer Cell Lines by Small Molecules Using the HyperCyt® High-Throughput Flow Cytometry System , 2009, Journal of biomolecular screening.

[25]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[26]  T. Ley,et al.  Commonly Dysregulated Genes in Murine Apl Cells , 2006 .

[27]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[28]  F. Tedeschi,et al.  HOXA9 gene expression in the chronic myeloid leukemia progression. , 2006, Leukemia research.

[29]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[30]  C. Wolf,et al.  Regioselective copper-catalyzed amination of bromobenzoic acids using aliphatic and aromatic amines. , 2006, The Journal of organic chemistry.

[31]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Bart De Moor,et al.  BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis , 2005, Bioinform..

[33]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[34]  E. Raymond,et al.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies , 1998, Investigational New Drugs.

[35]  G. Schuster,et al.  Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides , 2004, Molecular and Cellular Biochemistry.

[36]  D. V. Cramer.  Brequinar sodium , 2004, Pediatric Nephrology.

[37]  H. Pinedo,et al.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies , 2004, Cancer Chemotherapy and Pharmacology.

[38]  B. Mitchell,et al.  A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools. , 2002, Molecular pharmacology.

[39]  T. Graf,et al.  Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. , 2000, Blood.

[40]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[41]  W. Knecht,et al.  Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. , 1998, Biochemical pharmacology.

[42]  Unnur Thorsteinsdottir,et al.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.

[43]  G. Sauvageau,et al.  Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  L. Grochow,et al.  Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). , 1990, Cancer research.

[45]  G. Weiss,et al.  Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390). , 1989, Cancer research.

[46]  P. Chambon,et al.  The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.

[47]  J. Griffin,et al.  Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. , 1983, The New England journal of medicine.

[48]  A. Jakubowski,et al.  Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. , 1979, Cancer research.

[49]  J. Yates,et al.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.

[50]  R. Miller,et al.  Mammalian dehydroorotate-ubiquinone reductase complex. , 1968, Canadian journal of biochemistry.